Fujian Yuanli Active CarbonLtd Valuation
Is 300174 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300174 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300174 (CN¥16.24) is trading above our estimate of fair value (CN¥1.27)
Significantly Below Fair Value: 300174 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300174?
Other financial metrics that can be useful for relative valuation.
What is 300174's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥5.87b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.3x |
Enterprise Value/EBITDA | 12.8x |
PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does 300174's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 31.4x | ||
002125 Xiangtan Electrochemical ScientificLtd | 19.8x | n/a | CN¥7.1b |
300848 Miracll ChemicalsLtd | 70.9x | 77.6% | CN¥6.2b |
300109 Boai NKY Medical Holdings | 13.1x | n/a | CN¥6.5b |
002057 Sinosteel New Materials | 21.9x | n/a | CN¥5.9b |
300174 Fujian Yuanli Active CarbonLtd | 21.8x | 25.0% | CN¥5.9b |
Price-To-Earnings vs Peers: 300174 is good value based on its Price-To-Earnings Ratio (21.8x) compared to the peer average (31.4x).
Price to Earnings Ratio vs Industry
How does 300174's PE Ratio compare vs other companies in the CN Chemicals Industry?
Price-To-Earnings vs Industry: 300174 is good value based on its Price-To-Earnings Ratio (21.8x) compared to the CN Chemicals industry average (33.3x).
Price to Earnings Ratio vs Fair Ratio
What is 300174's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 21.8x |
Fair PE Ratio | 21.1x |
Price-To-Earnings vs Fair Ratio: 300174 is expensive based on its Price-To-Earnings Ratio (21.8x) compared to the estimated Fair Price-To-Earnings Ratio (21.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.